Home > Publications Database > Late effects of adjuvant chemotherapy for adult onset non-CNS cancer; cognitive impairment, brain structure and risk of dementia. > print

001     137061
005     20240614154542.0
024 7 _ |a 10.1016/j.critrevonc.2013.04.002
|2 doi
024 7 _ |a pmid:23768778
|2 pmid
024 7 _ |a 1040-8428
|2 ISSN
024 7 _ |a 1879-0461
|2 ISSN
024 7 _ |a altmetric:45300185
|2 altmetric
037 _ _ |a DZNE-2020-03383
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Koppelmans, Vincent
|b 0
245 _ _ |a Late effects of adjuvant chemotherapy for adult onset non-CNS cancer; cognitive impairment, brain structure and risk of dementia.
260 _ _ |a Amsterdam [u.a.]
|c 2013
|b Elsevier Science
264 _ 1 |3 print
|2 Crossref
|b Elsevier BV
|c 2013-10-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1718372695_614
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Few studies have investigated the late (i.e. ≥ 5 years post-treatment) effects of chemotherapy for non-central nervous system (non-CNS) cancer on the brain. Here we discuss the studies that have investigated the late effects of adjuvant chemotherapy for non-CNS cancer on cognitive function (n=6); brain structure and function (n=5); and incidence of dementia (n=4). The neuropsychological studies showed long-term adverse cognitive problems in chemotherapy-exposed breast cancer survivors. This is in line with results from neuroimaging studies that report long-term brain structural alterations after chemotherapy. The studies exploring the association between chemotherapy and the incidence of dementia were contradictive and showed no clear relationship between the two phenomena. Although several methodological issues limit the validity and interpretation of some of the results of these studies, they suggest that chemotherapy is associated with subtle, yet long-lasting cognitive deficits, possibly related to brain structural and functional differences, but as yet not with an increased risk of dementia.
536 _ _ |a 345 - Population Studies and Genetics (POF3-345)
|0 G:(DE-HGF)POF3-345
|c POF3-345
|f POF III
|x 0
542 _ _ |i 2013-10-01
|2 Crossref
|u https://www.elsevier.com/tdm/userlicense/1.0/
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Antineoplastic Agents
|2 NLM Chemicals
650 _ 2 |a Age Factors
|2 MeSH
650 _ 2 |a Antineoplastic Agents: adverse effects
|2 MeSH
650 _ 2 |a Antineoplastic Agents: therapeutic use
|2 MeSH
650 _ 2 |a Antineoplastic Combined Chemotherapy Protocols: adverse effects
|2 MeSH
650 _ 2 |a Antineoplastic Combined Chemotherapy Protocols: therapeutic use
|2 MeSH
650 _ 2 |a Brain: drug effects
|2 MeSH
650 _ 2 |a Brain: pathology
|2 MeSH
650 _ 2 |a Chemotherapy, Adjuvant: adverse effects
|2 MeSH
650 _ 2 |a Cognition Disorders: diagnosis
|2 MeSH
650 _ 2 |a Cognition Disorders: etiology
|2 MeSH
650 _ 2 |a Dementia: diagnosis
|2 MeSH
650 _ 2 |a Dementia: etiology
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Mental Disorders: diagnosis
|2 MeSH
650 _ 2 |a Mental Disorders: etiology
|2 MeSH
650 _ 2 |a Neoplasms: complications
|2 MeSH
650 _ 2 |a Neoplasms: drug therapy
|2 MeSH
650 _ 2 |a Neuroimaging
|2 MeSH
650 _ 2 |a Neuropsychological Tests
|2 MeSH
650 _ 2 |a Risk
|2 MeSH
650 _ 2 |a Survivors
|2 MeSH
700 1 _ |a Breteler, Monique M B
|0 P:(DE-2719)2810403
|b 1
|u dzne
700 1 _ |a Boogerd, Willem
|b 2
700 1 _ |a Seynaeve, Caroline
|b 3
700 1 _ |a Schagen, Sanne B
|0 P:(DE-HGF)0
|b 4
|e Corresponding author
773 1 8 |a 10.1016/j.critrevonc.2013.04.002
|b : Elsevier BV, 2013-10-01
|n 1
|p 87-101
|3 journal-article
|2 Crossref
|t Critical Reviews in Oncology/Hematology
|v 88
|y 2013
|x 1040-8428
773 _ _ |a 10.1016/j.critrevonc.2013.04.002
|g Vol. 88, no. 1, p. 87 - 101
|0 PERI:(DE-600)2025731-4
|n 1
|q 88:1<87 - 101
|p 87-101
|t Critical reviews in oncology, hematology
|v 88
|y 2013
|x 1040-8428
856 4 _ |u https://pub.dzne.de/record/137061/files/DZNE-2020-03383_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/137061/files/DZNE-2020-03383_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:137061
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2810403
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-345
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Population Studies and Genetics
|x 0
914 1 _ |y 2013
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CRIT REV ONCOL HEMAT : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1120
|2 StatID
|b BIOSIS Reviews Reports And Meetings
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-2719)1012001
|k AG Breteler
|l Population Health Sciences
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1012001
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21